Phase I Trial of Combretastatin A-4 Phosphate with Carboplatin
Joshua H. Bilenker(University of the Sciences), Peter J. O’Dwyer(University of Pennsylvania), Keith T. Flaherty(Cancer Research Center), David J. Vaughn(University of Pennsylvania), Mitchell D. Schnall(California University of Pennsylvania), Ross Zimmer(Regional Cancer Center), Bruce J. Giantonio(Northwestern University), Maryann Gallagher(Regional Cancer Center), Mark Rosen(California University of Pennsylvania), Lisa E. Davis(University of the Sciences), James Stevenson(Cleveland Clinic), Weijing Sun(University of Kansas Medical Center)
Cited by 99
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography
|CA A Cancer Journal for Clinicians|2007|2.6k